Exchange: NASDAQ·Updated 07:42 PM EST
BNTX logo

BNTX BioNTech SE - ADR

$81.12
$0.42
(0.52%)
Today
Closed $80.96
$0.16
(0.20%)
After Hours
Reported EarningsNov 3
Mkt Cap$20.07B
Vol1.71M

About BNTX

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.
36

Bearish Sentiment

How do you feel about BNTX?

moneybag888
$BNTX $MRNA “The smaller the float, the bigger the squeeze potential. Less supply, more explosive upside when demand hits!” 🔥
2
6
toast123
$BNTX has one of the strongest balance sheets in biotech, with substantial cash and liquid investments (>80% of its current market cap) and minimal debt. The market seems to be assigning very little value to its oncology pipeline. In my view, the ESMO 2026 results have been encouraging so far!
1
4
Sergey_stockdoc
$BNTX As stated, this will continue dropping with Moderna due to assymetric risk, especially when the pipeline is years out. I reiterate my $80 assumption.
1
3
toast123
$BNTX Current $22B market cap for BNTX reminds me of how cheaply the market valued Moderna when it was trading below $30 not long ago.
4
Rayvio_News_Filter
$BNTX · $BMY 🏥 BioNTech SE and Bristol-Myers Squibb Company reported Phase 2 data for pumitamig plus docetaxel in advanced NSCLC after progression on immunotherapy plus chemotherapy, showing a confirmed objective response rate of 36.7% and median progression-free survival of 6.9 months. Prioritized by relevance
4
Moniex
$BNTX Earnings won't send this but a major trial success will. Pumitamig is the most promising asset that could treat multiple cancers including pancreatic, colorectal, liver, NSCLC etc. Patience could earn great rewards here.
3
AIIAAIIA_88
$BNTX To think I chose to pick BNTX over MRNA... SMH. But, still, BNTX has huge potential. I am not giving up. JMO
2
Sergey_stockdoc
$BNTX I still stand by this. This has only been held up because Moderna is trading where it is, if Moderna drops further, which it likely will, then this will go to $80 and likely stay sideways until news comes out but it’s years behind any approval.
2
eightytwentie
$BNTX has sufficient cash but unproven mRNA efficacy $MRNA has insufficient cash but proven mRNA efficacy They should merge and accelerate the future of cancer immunotherapy
2
LiveSquawk
$BNTX | BioNTech Q3 2026 Earnings - Adj EPS: €1.76 - Rev: €1.29B (est €1.02B) - Oper Income: €125.0M - Sees FY Re: €1.70B To €1.90B (previously €1.60B To €1.90B) - Still Sees FY R&D Expenses: €2.00B To €2.30B
2
eightytwentie
$BNTX no way for $AZN TO ENTER THE MRA MARKET UNLESS IT LICENSES IT FROM MODERNA OR BIONTECH. MOST LIKELY ASTRAZENECA WILL JUST BUY BIONTECH SINCE BIOTECH IS IN GERMANY AND ALSO EUROPEAN AND THEN IT GETS THE FULL FREEDOM TO ENTER THE MARKET. All caps for emphasis
2
IndyOne
$BNTX Another failure. CEO and CMO leaving makes perfect sense. Their ideas did not work.
2
filecrux
$BNTX Follow-up: German drugmaker BioNTech's HER2 drug beat chemo in breast cancer only modestly. 🏢 BioNTech is a Mainz-based cancer drug developer worth about $22.28B at $88.115 a share at 16:00 ET on October 23, 2026, with €7.68B of cash and cash equivalents as of December 31, 2025 📉 The companies say the benefit would be limited in HR+/HER2-low metastatic breast cancer, and lung inflammation (ILD) was more frequent than in earlier trials, with a small share of severe or fatal cases ✅ On the other side, the trial did meet its primary endpoint, and the drug is still in a second Phase 3 trial in HER2-expressing endometrial cancer and a Phase 1/2 solid-tumor trial, among the 13 Phase 3 trials BioNTech says it is running 📅 Next: BioNTech and DualityBio say they will discuss the data and decide next steps; no date given Source: SEC 6-K, Oct 26 + SEC 6-Ks, Oct 13 and Oct 19
2
Rayvio_News_Filter
$BNTX 🏥 BioNTech SE and DualityBiologics (Suzhou) Co., Ltd. reported topline Phase 3 DYNASTY-Breast02 results showing trastuzumab pamirtecan met the primary endpoint with a statistically significant but modest progression-free survival improvement versus chemotherapy in chemotherapy-naïve HR+/HER2-low metastatic breast cancer; overall survival data were immature and interstitial lung disease rates were higher. Curated for market relevance
2
IndyOne
$BNTX This is a "no touch". Really amazing that the CEO and CMO are leaving to establish a new and separate company with BNTX technology. When does the new CEO arrive that has no mRNA experience? ANSWER: February 2027. So, let's get this straight, the current CEO is negotiating with himself on terms to use and take BNTX technology. You see the governance and conflict of interest issue? BNTX presentation on Lung-107 pivotal on Sunday. So far, just a string of clinical failures. This company is leaderless.
2
eightytwentie
$BNTX AstraZeneca missed out on mRNA covid vaccine $ but is interested in entering the mRNA cancer vaccine market. They’ve started building a team. Biontech has had poor mRNA efficacy thus far but is cash rich and has other modalities eg ADC. Moderna had high efficacy but low cash. $MRNA An effective strategy would be for Biontech and Moderna to merge to accelerate each others respective pipelines and build a moat against the AstraZeneca giant who has huge FCF and $8B in cash.
1
StocktwitsEarnings
$BNTX Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $1.99 down -45.48% YoY • Reported revenue of $1.49B down -16.21% YoY • BioNTech raised its FY 2026 revenue guidance midpoint to 17T; adjusted R&D expenses guidance of 20T and adjusted SG&A expenses guidance of 700.8B remain unchanged for the full year.

Advertisement|Remove ads.